Department of Anesthesiology
Author [ Title(Desc)] Type Year
Filters: Keyword is Neuromuscular Nondepolarizing Agents  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Savarese JJ, Lien CA, Belmont MR.  1995.  The accuracy of the 5%-25% (T1-T3) twitch recovery interval in predicting the speed of spontaneous recovery from mivacurium-induced neuromuscular blockade.. Anesth Analg. 80(1):209-10.
Kopman AF, Kopman DJ, Ng J, Zank LM.  2005.  Antagonism of profound cisatracurium and rocuronium block: the role of objective assessment of neuromuscular function.. J Clin Anesth. 17(1):30-5.
Savarese JJ, Lien CA, Belmont MR.  1996.  Antagonism of residual mivacurium blockade: setting the record straight.. Anesthesiology. 84(6):1525-8.
B
Boros EE, Bigham EC, Boswell GE, Mook RA, Patel SS, Savarese JJ, Ray JA, Thompson JB, Hashim MA, Wisowaty JC et al..  1999.  Bis- and mixed-tetrahydroisoquinolinium chlorofumarates: new ultra-short-acting nondepolarizing neuromuscular blockers.. J Med Chem. 42(2):206-9.
C
Heerdt PM, Kang R, The' A, Hashim M, Mook RJ, Savarese JJ.  2004.  Cardiopulmonary effects of the novel neuromuscular blocking drug GW280430A (AV430A) in dogs.. Anesthesiology. 100(4):846-51.
Savarese JJ, Ali HH, Basta SJ, Scott RP, Embree PB, Wastila WB, Abou-Donia MM, Gelb C.  1989.  The cardiovascular effects of mivacurium chloride (BW B1090U) in patients receiving nitrous oxide-opiate-barbiturate anesthesia.. Anesthesiology. 70(3):386-94.
Savarese JJ, Lien CA, Belmont MR, Rubin L.  1995.  The clinical and basic pharmacology of mivacurium: a short-acting nondepolarizing benzylisoquinolinium diester neuromuscular blocking drug.. Acta Anaesthesiol Scand Suppl. 106:18-22.
Savarese JJ, Ali HH, Basta SJ, Embree PB, Scott RP, Sunder N, Weakly JN, Wastila WB, el-Sayad HA.  1988.  The clinical neuromuscular pharmacology of mivacurium chloride (BW B1090U). A short-acting nondepolarizing ester neuromuscular blocking drug.. Anesthesiology. 68(5):723-32.
Basta SJ, Ali HH, Savarese JJ, Sunder N, Gionfriddo M, Cloutier G, Lineberry C, Cato AE.  1982.  Clinical pharmacology of atracurium besylate (BW 33A): a new non-depolarizing muscle relaxant.. Anesth Analg. 61(9):723-9.
Savarese JJ, Ali HH, Basta SJ, Sunder N, Moss J, Gionfriddo MA, Lineberry CG, Wastila WB, el-Sayad HA, Montague D et al..  1983.  The clinical pharmacology of BW A444U. A nondepolarizing ester relaxant of intermediate duration.. Anesthesiology. 58(4):333-41.
Basta SJ, Savarese JJ, Ali HH, Embree PB, Schwartz AF, Rudd GD, Wastila WB.  1988.  Clinical pharmacology of doxacurium chloride. A new long-acting nondepolarizing muscle relaxant.. Anesthesiology. 69(4):478-86.
Belmont MR, Lien CA, Tjan J, Bradley E, Stein B, Patel SS, Savarese JJ.  2004.  Clinical pharmacology of GW280430A in humans.. Anesthesiology. 100(4):768-73.
Ali HH, Savarese JJ, Embree PB, Basta SJ, Stout RG, Bottros LH, Weakly JN.  1988.  Clinical pharmacology of mivacurium chloride (BW B1090U) infusion: comparison with vecuronium and atracurium.. Br J Anaesth. 61(5):541-6.
Savarese JJ, Lien CA, Belmont MR, Wastila WB.  1997.  [The clinical pharmacology of new benzylisoquinoline-diester compounds, with special consideration of cisatracurium and mivacurium].. Anaesthesist. 46(10):840-9.
Savarese JJ.  1986.  Clinical relaxation: current controversy.. Can Anaesth Soc J. 33(3 Pt 2):S1-4.
Wastila WB, Maehr RB, Turner GL, Hill DA, Savarese JJ.  1996.  Comparative pharmacology of cisatracurium (51W89), atracurium, and five isomers in cats.. Anesthesiology. 85(1):169-77.
Lebowitz PW, Savarese JJ.  1980.  Complications involving neuromuscular pharmacology.. Int Anesthesiol Clin. 18(3):139-56.
D
Kopman AF, Lien CA, Naguib M.  2010.  Determining the potency of neuromuscular blockers: are traditional methods flawed? Br J Anaesth. 104(6):705-10.
Savarese JJ, Kitz RJ.  1975.  Does clinical anesthesia need new neuromuscular blocking agents? Anesthesiology. 42(3):236-9.
E
Ali HH, Savarese JJ, Basta SJ, Sunder N, Gionfriddo M.  1983.  Evaluation of cumulative properties of three new nondepolarizing neuromuscular blocking drugs BW A444U, atracurium and vecuronium.. Br J Anaesth. 55 Suppl 1:107S-111S.
F
Lien CA, Savard P, Belmont M, Sunaga H, Savarese JJ.  2009.  Fumarates: unique nondepolarizing neuromuscular blocking agents that are antagonized by cysteine.. J Crit Care. 24(1):50-7.
Savarese JJ, Wastila WB.  1995.  The future of the benzylisoquinolinium relaxants.. Acta Anaesthesiol Scand Suppl. 106:91-3.
M
Kopman AF, Klewicka MM, Kopman DJ, Neuman GG.  1999.  Molar potency is predictive of the speed of onset of neuromuscular block for agents of intermediate, short, and ultrashort duration.. Anesthesiology. 90(2):425-31.
N
Lien CA, Belmont MR, Abalos A, Hass D, Savarese JJ.  1999.  The nature of spontaneous recovery from mivacurium-induced neuromuscular block.. Anesth Analg. 88(3):648-53.
Lien CA.  2010.  Neostigmine: how much is necessary for patients who receive a nondepolarizing neuromuscular blocking agent? Anesthesiology. 112(1):16-8.